Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.

Show more
Type
Subsidiary
Parent Company
GlaxoSmithKline
HQ
Basel, CH
Founded
1996
Novartis was founded in 1996 and is headquartered in Basel, CH
Report incorrect company information

Key People/Management at Novartis

Vas Narasimhan

Vas Narasimhan

CEO of of Novartis AG
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research (NIBR
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
F. Ball

F. Ball

CEO, Alcon
Steven Baert

Steven Baert

Head of Human Resources of Novartis
Harry Kirsch

Harry Kirsch

Chief Financial Officer of Novartis
Show more

Novartis Office Locations

Novartis has offices in Basel, New York, East Hanover, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
East Hanover, US
1 Health Plazam, Bldg. 101
New York, US
230 Park Avenue, 21st Floor
Show all (6)
Report incorrect company information

Novartis Financials and Metrics

Summary Metrics

Founding Date

1996
Novartis is a subsidiary of GlaxoSmithKline

Novartis Financials

Novartis's revenue was reported to be $48.52 b in FY, 2016 which is a 1.8% decrease from the previous period.
USDFY, 2014FY, 2015FY, 2016

Revenue

53.6 b49.4 b48.5 b

Revenue growth, %

(8%)(2%)

Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AveXis $8.70 b
Advanced Accelerator Applications October 30, 2017$3.90 b
Report incorrect company information

Novartis News and Updates

Novartis pads case for new MS blockbuster with disease-progression analysis

Novartis is hoping its multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help secure it a blockbuster approval. And now it has more data to put toward that case.

Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year

Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening. Rejected by the FDA earlier this year, the copycat needs a small bridging study before the agency can take another look, CEO Vas Narasimhan said.

Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis

Novartis’s first-quarter sales and earnings beat consensus analyst estimates. So why did the company’s stock dip more than 2% first thing Thursday? The answer speaks to investors' high expectations for its new CEO, Vas Narasimhan—and for his promise to focus on markets that can drive earnings growth…

Greek lawmakers hand off probe of politicians accused of taking Novartis bribes: report

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

UPDATE 3-New Novartis CEO feels heat on U.S. generics business

* Cosentyx sales miss average analyst forecast (Recasts story to focus on Cosentyx, Sandoz; adds share performance)
Show more
Report incorrect company information